Academic Profile : Faculty

Prof Gerhard Gruber_1.JPG picture
Prof Gerhard Gruber
Professor, School of Biological Sciences
Date of 1st Appointment: 11th of August 2005
Present Appointment: Associate Professor

● Academic Qualification
2002 Ph.D. (habil.) in Biochemistry and Molecular Biology, University of the Saarland, Germany
2001 Ph.D. (habil.) in Biochemistry, University of Osnabrück, Germany
1995 Ph.D. (rer. nat.) in Biochemistry, Johannes Gutenberg-University Mainz, Germany
1992 Diploma Degree, Johannes Gutenberg-University Mainz, Germany

● Administrative involvements
1. Deputy Head of Division of Structural and Computational Biology, School of Biological Sciences,
Nanyang Technological University
2. Member of the Steering committee of the Singapore Bioimaging Consortium (SBIC)
Research Activities
The research group on Structure and function of molecular motors of A/Prof. G. Gruber in the Division of Structural and Computational Biology, SBS, NTU, is recognized for their expertise in determining the relationships between the structure and function of the so-called A1AO ATP synthases, V1VO ATPases, F1FO ATP synthases and AAA-ATPases. These enzymes are proposed to be the smallest biological motor proteins (nano-motor proteins). In order to get inside into the structure of these multi-subunit membrane complexes techniques like single particle analysis of electron micrographs, solution X-ray scattering, X-ray crystallography and NMR-spectroscopy are used. The functional and dynamical processes inside these enzymes are studied by fluorescence spectroscopy (e.g. FRET, FCS, intrinsic fluorescence spectroscopy) and biochemical approaches.
  • Identifying novel targets and designing new anti-TB agents through understanding the Mycobacterial stringent response to stress
  • Project 1: Structural Biology and Biochemistry
  • Project 4: Screening, lead optimization and pre-clinical development (A*STAR Team PI: Damian O’Connell)
  • Project 5: Clinical microbiology (TTSH Team PI: Albert Lim Yick Hou)
  • Targeting energy of life for the development of drug combination to eradicate antibiotic-tolerant Mycobacterium abscessus, a clinical nightmare
US 2020/0231550 A1: Compounds for Treating Tuberculosis (2021)
Abstract: The present invention relates to pyrimidine compounds and compositions for treating tuberculosis. These compounds may be used to target the F1 domain of F-ATP synthase and may be used with bedaquiline or 6-chloro-2-ethyl-N-[[4-[4-[4-(trifluoromethoxy)phenyl]piperidin-1-yl]phenyl]methyl]imidazo[1,2-a]pyridine-3-carboxamide (Q203) or a combination thereof.
1995 - 1996, Postdoc-Fellowship of the German academical exchange service (DAAD)
1997 - 1999, Fellowship of the Human Frontiers Science Programs (HFSP)
2000 - 2001, Habilitation-Fellow of the German Research Foundation (DFG)